These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36549393)

  • 1. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine).
    Bavli Y; Chen BM; Gross G; Hershko A; Turjeman K; Roffler S; Barenholz Y
    J Control Release; 2023 Feb; 354():316-322. PubMed ID: 36549393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.
    Ju Y; Lee WS; Pilkington EH; Kelly HG; Li S; Selva KJ; Wragg KM; Subbarao K; Nguyen THO; Rowntree LC; Allen LF; Bond K; Williamson DA; Truong NP; Plebanski M; Kedzierska K; Mahanty S; Chung AW; Caruso F; Wheatley AK; Juno JA; Kent SJ
    ACS Nano; 2022 Aug; 16(8):11769-11780. PubMed ID: 35758934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Kozma GT; Mészáros T; Berényi P; Facskó R; Patkó Z; Oláh CZ; Nagy A; Fülöp TG; Glatter KA; Radovits T; Merkely B; Szebeni J
    Vaccine; 2023 Jul; 41(31):4561-4570. PubMed ID: 37330369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration.
    Guerrini G; Gioria S; Sauer AV; Lucchesi S; Montagnani F; Pastore G; Ciabattini A; Medaglini D; Calzolai L
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.
    Münter R; Sørensen E; Hasselbalch RB; Christensen E; Nielsen SD; Garred P; Ostrowski SR; Bundgaard H; Iversen KK; Andresen TL; Larsen JB
    Mol Pharm; 2023 Jul; 20(7):3356-3366. PubMed ID: 36952227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy.
    Koller A; Szebeni J
    Hum Vaccin Immunother; 2023 Dec; 19(1):2188035. PubMed ID: 37062957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
    Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
    J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Zhou ZH; Cortese MM; Fang JL; Wood R; Hummell DS; Risma KA; Norton AE; KuKuruga M; Kirshner S; Rabin RL; Agarabi C; Staat MA; Halasa N; Ware RE; Stahl A; McMahon M; Browning P; Maniatis P; Bolcen S; Edwards KM; Su JR; Dharmarajan S; Forshee R; Broder KR; Anderson S; Kozlowski S
    Vaccine; 2023 Jun; 41(28):4183-4189. PubMed ID: 37244808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
    Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
    Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotyping of IgE-Mediated Polyethylene Glycol and/or Polysorbate 80 Allergy.
    Ieven T; Coorevits L; Vandebotermet M; Tuyls S; Vanneste H; Santy L; Wets D; Proost P; Frans G; Devolder D; Breynaert C; Bullens DMA; Schrijvers R
    J Allergy Clin Immunol Pract; 2023 Oct; 11(10):3146-3160. PubMed ID: 37380070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
    Carreño JM; Singh G; Tcheou J; Srivastava K; Gleason C; Muramatsu H; Desai P; Aberg JA; Miller RL; Study Group P; Pardi N; Simon V; Krammer F
    Vaccine; 2022 Oct; 40(42):6114-6124. PubMed ID: 36115801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines.
    Mouri M; Imamura M; Suzuki S; Kawasaki T; Ishizaki Y; Sakurai K; Nagafuchi H; Matsumura N; Uchida M; Ando T; Yoshioka K; Ooka S; Sugihara T; Miyoshi H; Mori M; Okada T; Yamaguchi M; Kunishima H; Kato M; Kawahata K
    Allergol Int; 2022 Oct; 71(4):512-519. PubMed ID: 35718709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes.
    Szebeni J; Kiss B; Bozó T; Turjeman K; Levi-Kalisman Y; Barenholz Y; Kellermayer M
    ACS Nano; 2023 Jul; 17(14):13147-13157. PubMed ID: 37417667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.